Small-molecule inhibitor-based therapies have significantly improved PFS outcomes in patients with CLL compared with chemoimmunotherapy outcomes, especially in patients with high-risk disease characteristics (e.g., del(17p) or TP53 mutations) (39, 56, 57). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.